Maria Tripaldella
Overview
Explore the profile of Maria Tripaldella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iannuzzo G, Cuomo G, Di Lorenzo A, Tripaldella M, Mallardo V, Iaccarino Idelson P, et al.
J Clin Med
. 2022 Jul;
11(14).
PMID: 35887846
Cardiovascular disease is the most important cause of death worldwide in recent years; an increasing trend is also shown in organ transplant patients subjected to immunosuppressive therapies, in which cardiovascular...
2.
Iannuzzi A, Giallauria F, Gentile M, Rubba P, Covetti G, Bresciani A, et al.
J Clin Med
. 2022 Jan;
11(1).
PMID: 35011818
Atherogenic lipoproteins (particularly, very low-density lipoproteins, VLDL) are associated with subclinical atherosclerosis. The present study aims at evaluating whether routinely analysed lipid parameters are associated with carotid intima-media thickness, a...
3.
Iannuzzo G, Buonaiuto A, Calcaterra I, Gentile M, Forte F, Tripaldella M, et al.
Nutr Metab Cardiovasc Dis
. 2022 Jan;
32(3):684-691.
PMID: 34991937
Background And Aims: Familial hypercholesterolemia (FH) is an autosomal dominant disease that leads to cardiovascular (CV) disease. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-I) demonstrated efficacy in low-density lipoprotein cholesterol...
4.
Anesi A, Di Minno A, Calcaterra I, Cavalca V, Tripaldella M, Porro B, et al.
Biomedicines
. 2021 Dec;
9(12).
PMID: 34944757
Rationale: Familial hypercholesterolemia (FH) is caused by mutations in genes involved in low-density lipoprotein cholesterol (LDL-C) metabolism, including those for pro-protein convertase subtilisin/kexin type 9 (PCSK-9). The effect of PCSK-9...
5.
Di Minno A, Orsini R, Chiesa M, Cavalca V, Calcaterra I, Tripaldella M, et al.
Biomedicines
. 2021 Aug;
9(8).
PMID: 34440277
Introduction: Familial hypercholesterolemia (FH) is characterized by extremely high levels of circulating low-density lipoprotein cholesterol (LDL-C) and is caused by mutations of genes involved in LDL-C metabolism, including LDL receptor...
6.
Iannuzzo G, Tripaldella M, Mallardo V, Morgillo M, Vitelli N, Iannuzzi A, et al.
Biomedicines
. 2021 Aug;
9(7).
PMID: 34356902
A number of epidemiologic studies have demonstrated a strong association between increasing lipoprotein a [Lp(a)] and cardiovascular disease. This correlation was demonstrated independent of other known cardiovascular (CV) risk factors....
7.
Forte F, Calcaterra I, Lupoli R, Orsini R, Chiurazzi M, Tripaldella M, et al.
Eur J Prev Cardiol
. 2021 Feb;
28(18):1980-1990.
PMID: 33624016
Aims: Lower limb peripheral artery disease (PAD) is a leading cause of atherosclerotic cardiovascular disease (ASCVD). Discordant data are available on the association between apolipoprotein and PAD. We performed a...
8.
Di Minno A, Gentile M, Iannuzzo G, Calcaterra I, Tripaldella M, Porro B, et al.
Thromb Res
. 2020 Nov;
194:229-236.
PMID: 33213848
Background: Treatment with protein convertase subtilisin kexin type 9 inhibitors (PCSK-9i) reduced cholesterol levels and cardiovascular events in patients with hypercholesterolemia. We assessed changes in lipid profile, oxidation markers and...